title: Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.
abstract: BACKGROUND
  RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type.
  
  
  METHODS
  An analysis was done of RBCT requirements and Hb recovery kinetic in the first 60 days after HLA-identical sibling allogeneic SCT in a series of 110 consecutive patients treated for various malignant diagnoses. Patients were prepared with either an antithymocyte globulin (ATG) and reduced intensity chemotherapy-based conditioning (RIC) (n=64) or a myeloablative conditioning regimens (MAC; n=46). Patients received marrow (n=64) or PBPCs (n=46).
  
  
  RESULTS
  Overall, intensity of conditioning regimen (RIC vs. MAC; p=0.0005) and graft source (PBPC vs. marrow; p<0.0001) independently predicted RBCT requirements. Hb recovery was accelerated after RIC when compared to MAC allo-SCT (p=0.02). In RIC patients, RBCTs were inversely correlated to Hb level before conditioning (p<0.0001) and the dose of ATG (p=0.009). Moreover, Hb level before allo-SCT significantly influenced Hb recovery kinetic after RIC but had no impact on RBCT requirements and Hb recovery after MAC.
  
  
  CONCLUSIONS
  Thus, RIC conditioning creates a different pattern of erythropoiesis recovery as compared to a MAC regimen and suggest a need for studies aimed at further reducing RBCT and accelerating Hb recovery.
authors.affiliation: Unit of Transplantation and Cellular Therapy, Institut Paoli Calmettes, Université de la Méditerranée, Marseille, France.
authors.forename: V
authors.initials: V
authors.lastname: Ivanov
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: K
authors.initials: K
authors.lastname: Bilger
authors.forename: P
authors.initials: P
authors.lastname: Ladaique
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: C
authors.initials: C
authors.lastname: Arnoulet
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: J
authors.initials: J
authors.lastname: Camerlo
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: V J
authors.initials: VJ
authors.lastname: Bardou
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data*; D004920:Erythropoiesis / Q000187:drug effects*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D011237:Predictive Value of Tests; D011379:Prognosis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins